• Project status: Active
Teenager looking out of window

Penguin study: clinical trial of pimavanserin capsules, a potential treatment for irritability associated with autism spectrum disorder (ASD)

Do you notice irritable behaviours in your child? If yes, Murdoch Children's Research Institute invites you to join the Penguin study.

Please note: This is an international study that is sponsored and funded by Acadia Pharmaceuticals.

Do you notice irritable behaviours in your child? If yes, Murdoch Children's Research Institute invites you to join the Penguin study.

Please note: This is an international study that is sponsored and funded by Acadia Pharmaceuticals.

Do you notice irritable behaviours in your child? If yes, Murdoch Children's Research Institute invites you to join the Penguin study.

Please note: This is an international study that is sponsored and funded by Acadia Pharmaceuticals.

Overview

Autism spectrum disorder (ASD) is a lifelong condition that affects the way the brain develops. It begins from birth and can cause difficulties in various aspects of life.

Sometimes autistic children may experience irritability. Currently, there is a lack of safe and effective treatment options for children and adolescents who experience this behavioural problem.

There is a clear need for autistic children and adolescents to have better treatment options for managing irritability, anxiety and distress.

This research study is evaluating an investigational drug called pimavanserin, to determine if it may treat irritability and other behaviours in children and adolescents with autism spectrum disorder.

Information for participants 

To participate in this autism research study, patients must:

  • Be aged five to 17 years old
  • Be diagnosed with autism spectrum disorder
  • Experience irritable behaviours because of their ASD
  • Have a parent or guardian able to participate as a study partner during the entire study
  • Be able to swallow a medium-sized capsule

Other eligibility criteria apply. Study participants will receive the study drug at no cost and may be compensated for travel. Patients will be asked to participate for up to 14 weeks.

This study is actively enrolling. Get in touch today to find out more.

Contact us

Penguin Study
Dr Kylie Crompton 
Research Officer 
Phone: +61 3 9936 6756
Email: 

child in hospital

Tomorrow's cures need your donations today

Donate now